CandlesenseCandlesense
News/Companies/BWAY

BWAY News

Neurolief Prepares for Launch of its Proliv™Rx System for Major Depressive Disorder with Strategic Investment from BrainsWay

BWAY

CORAL SPRINGS, Fla. and NETANYA, Israel, Aug. 21, 2025 /PRNewswire/ -- Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced a strategic investment from BrainsWay Ltd. (NASDAQ & TASE: BWAY), a publicly-traded global...

August 21, 2025Funding
Read more →

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

BWAY

This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home

August 21, 2025Mergers
Read more →

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

BWAY

June 12, 2025
Read more →

BrainsWay Sees Comparable Results Between Accelerated And Standard Deep TMS In Major Depression Patients

BWAY

June 11, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

BWAY

June 9, 2025
Read more →

Brainsway Enters Into Strategic Equity Financing Agreement With Stella MSO; To Invest $5M In Stella

BWAY

June 4, 2025
Read more →

BrainsWay Affirms FY2025 Sales Guidance of $49.00M-$51.00M vs $179.75M Est

BWAY

May 13, 2025
Read more →

BrainsWay Q1 EPS $0.02 Misses $0.09 Estimate, Sales $11.54M Miss $41.39M Estimate

BWAY

May 13, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

BWAY

March 12, 2025
Read more →

BrainsWay Expects 2025 Sales Of $49M-$51M, Up 20%-24% Growth Over 2024 Revenue, Anticipating Continued Profitability And Positive Cash Flow, Targeting Operating Income Of 3%-4% And Adjusted EBITDA Of 11%-12% For Full-year 2025

BWAY

March 11, 2025
Read more →

BrainsWay Q4 GAAP EPS Of $0.04 Vs. $0.00 YoY, Sales Of $11.41M Vs. $9.03M YoY

BWAY

March 11, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

BWAY

December 23, 2024
Read more →

BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A Peer-

BWAY

November 20, 2024
Read more →

BrainsWay Announces Private Insurance Coverage From Cigna Corporation For Treatment Of OCD Utilizing Deep TMS

BWAY

September 14, 2022
Read more →

BrainsWay Highlights Will Present Expanded Post-Marketing Research For Major Depressive Disorder At Clinical Transcranial Magnetic Stimulation Society Meeting

BWAY

May 4, 2022
Read more →